Safety Monitoring of COVID Vaccines and Perception of Post-vaccination Side-Effects: Preliminary Findings From The First Month of Routine Monitoring in a Hospital Vaccination Setting of China

Aihua Feng (aihuafeng2013@163.com)  
The Fourth People's Hospital of Jinan  https://orcid.org/0000-0002-6632-1152

Ruoyan Gai Tobe  
National Institute of Population and Social Security Research Japan

Yongqiang Wang  
The Fourth People's Hospital of Jinan

Ting Yang  
The Fourth People's Hospital of Jinan

Xiuting Mo  
Ritsumeikan University: Ritsumeikan Daigaku

Limei Zhao  
The Fourth People's Hospital of Jinan

Research note

Keywords: COVID-19 vaccines, vaccination uptake, safety, pandemic, China

DOI: https://doi.org/10.21203/rs.3.rs-471134/v1

License: ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Objectives: This study aims to explore the occurrence of post-vaccination side-effects from COVID-19 vaccines and its affecting factors in a hospital vaccination setting of China.

Results: A total of 811 vaccinees aged 17 to 58 years, who finished the full package of two doses in February 2021, have been recruited at the second vaccination uptake. Among all, there have been 66 participants who reported one or more mild side effects, while none of them developed severe cases. Those with history of immune deficiency were more likely to report side effect(s). Although with several concerns, most participants showed willingness to get vaccinated (98.8%) with relevant high proportions of perceived safety (99.5%) and effectiveness (97.3%).

Introduction

The COVID-19 pandemic has swept throughout the world and posed multifaceted substantial challenges in public health, the economy and society. To mitigate the pandemic, safe and effective vaccines are urgently needed. Development of vaccines was initiated when the genetical sequence of the virus was available in January 2020, since then more than 200 candidates derived from multiple platforms, including inactivated vaccines, live virus vaccines, recombinant protein vaccines, vectored vaccines, and DNA or RNA vaccines, have jointed the race and strived to pass the clinical evaluation stages, gradually adding knowledge on the nature of protective immune responses to COVID-19.

In China, two inactivated vaccines Sinopharm and Sinovac have been recently approved with conditional marketing authorization for emergency-use in December 2020 and February 2021, respectively. Then, the vaccination has been at first initiated targeting people who are occupationally exposed to high-risk of the infection, including those engaging in cold-chain imports and quarantine at ports / airports, maritime pilot, air crew, those working at fresh markets, those engaging in public transportation, healthcare staffs and those planning to go abroad in a short term, for border enforcement to prevent the imported cases. For the nationwide uptake, it is expected to expand the vaccination coverage in stages, and high-risk populations are prioritized. On the other hand, limited knowledge on safety and effectiveness have provoked vaccine hesitancy domestically and globally as well.

To this end, since rolling out the vaccination in the hospital setting, we have initiated routine monitoring the occurrence of post-vaccination side effects from the vaccines and its affecting factors, in order to inform the large-scale uptake. This short report summarized latest findings of the effort.

Methods

The study has investigated those with good health status who were vaccinated with the full package of two doses at the vaccination center of a tertiary hospital in Jinan, China, in February 2021. They were derived from the key target groups with occupational exposure to the high-risk infection. We invited them to a brief online survey after two weeks of getting vaccinated via Wechat, an overwhelmingly used social
network application in China. A total of 811 vaccinees have been eventually recruited and completed the online questionnaire, which included basic demographical information, the occurrence, duration and severity of self-reported post-vaccination side effects as listed in Table 1. Data collection was closed on March 16, 2021. The study has been approved by the ethical committee of the Fourth People's Hospital of Jinan, China.

Data were analyzed by using Stata 15.0. At first, participants’ attitude to the vaccination and the occurrence of self-reported post-vaccination side effects were summarized by using univariate analysis. Then, a multivariate regression analysis was performed to determine independent factors affecting the occurrence of the side effects.

Results

Table 2 reflected participants’ perception aspects to the vaccination, including knowledge on the vaccines, the main reason to get vaccinated, willingness to get vaccinated, recommendation to others, concerns on the vaccines, perceived effectiveness, and perceived safety. Regarding knowledge on the vaccines, among 811 vaccinees, 69.8% perceived themselves knowing a little and 25.9% having good knowledge. For the main reason to get vaccinated, a majority of the vaccines answered either occupational exposure to the high-risk (39.5%) or planning to go aboard (51.9%). Most of them showed willingness to get vaccinated (98.8%) and to recommend to others (96.2%), with relevant high proportions of perceived safety (99.5%) and effectiveness (97.3%). The detailed concerns on the vaccines included getting infected after vaccination (69/811, 8.5%), ineffectiveness for the mutant strain (195/811, 24.0%), unknown risks due to the short time on the market (232/811, 28.6%), and unknown length of the protection period (191/811, 23.6%).

Among 811 vaccinees, there have been 66 participants who reported one or more side effects (8.1%), which was fully listed in Table 3. All of these symptoms disappeared within 2 weeks. The most frequently reported side effects were including soreness in the injection site (46 vaccinees), somnolence (38 vaccinees), and tiredness (31 vaccinees). On the other hand, there was no severe cases that required clinical measures as the results of monitoring these participants. We input the age group by 10 years, educational background, occupation, history of allergy, history of immune deficiency and type of the vaccines in the multivariate regression analysis. The result suggested those with history of immune deficiency were more likely to report side effect(s) (OR=4.16, 95% CI: 1.03-16.85), while other factors did not have significant impact on the target outcome.

Discussion

To our knowledge, this is the first short report on side effects of the COVID vaccines in China. The latest monitoring results indicated an overall low-level occurrence of side effects, mostly manifesting mild temporary symptoms including inoculation site, somnolence and fatigue. To date, we confirmed that no severe case has been reported. The online survey also revealed overwhelm proportion of perceived safety
(99.5%) and effectiveness (97.3%), though concerning issues remain in terms of getting infected after vaccination, ineffectiveness for the mutant strain, unknown risks due to the short time on the market, and unknown length of the protection period.

The latest findings on the ground nevertheless are informative to the upcoming expanded nationwide vaccination. The current low-level occurrence of mild and temporary side effects is in favor of the vaccine safety and supportive to the uptake of the universal vaccination by improving the acceptance and dismantling the behavioral barriers, which remained as a spreading concern substantially due to limited information on the safety in China and the world\textsuperscript{7-8}. With expanding of the large-scale vaccination, more monitoring data from both research and real-world are expected to further fill the knowledge gap.

**Limitations**

It is worthy to note potential limitations when interpreting these findings. First, our small-scale investigation derived from a relevantly short period of observation as a part of the ongoing routine monitoring in one hospital vaccination setting, and therefore have limited capacity to identify all adverse outcomes of the vaccination. Another fact limiting this capacity is that the investigation was in the initial phrase of the vaccination campaign in China, merely targeting those occupationally exposed to the high-risk infection, whereas the nationwide vaccination is gradually expanding to the general population. Moreover, these side effects as showed in the results were based on the self-report of the vaccinees, which is the first step of our routine monitoring to identify the occurrence, duration and severity of adverse reactions via the social networking platform, consequently followed by tracking the symptoms and necessary clinical procedures for severe / emergent or long-lasting cases (more than two weeks). To date, no serological test to identify the antibody level has been implemented in the study setting.

**Declarations**

**Ethics approval and consent to participate**

The study has been approved by the ethical committee of the Fourth People’s Hospital of Jinan. All participants read and signed the informed consent before filling out the questionnaire.

**Consent for publication**

All the authors agreed to publish the manuscript.

**Competing interests**

The authors declare no potential conflict of interest.

**Funding**

No external funding for this manuscript.
Authors’ contributions

AF designed and organized the study; RGT designed the study, conducted the data analysis and paper writing; YW, TY and LZ were responsible for the field work and participants recruiting; XM designed the questionnaire and review the manuscript.

Acknowledgements

We appreciate all the participants who attended this research for their kindly cooperation, and we would like to thank every effort made by the Vaccination clinic medical staff from the Fourth People’s Hospital of Jinan.

Availability of data and materials

Please contact corresponding author for further information if interested.

References

1. Zhao J, Zhao S, Ou J, et al. COVID-19: Coronavirus vaccine development updates. Frontiers in immunology. 2020;11:602256.
2. Wang H, Zhang Y, Huang B, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020;182:713–21.
3. Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infectious Diseases. 2021;21:181–92.
4. Dror AA, Eisenbach N, Taiber S, et al. Vaccine hesitancy: the next challenge in the fight against COVID. European Journal of Epidemiology. 2020;25:755–9.
5. Reiter PL, Pennell ML, Katz ML. Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated. Vaccine. 2020;38:6500–7.
6. Lin Y, Hu Z, Zhao Q, et al. Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China. PLoS Neglected Tropical Diseases. 2020;14:e0008961.
7. Guidry JP, Laestadius LI, Vraga EK, et al. Willingness to get the COVID-19 vaccine with and without emergency use authorization. Am J Infect Control. 2021;49:137–42.
8. Gan L, Chen Y, Hu P, et al. Willingness to receive SARS-CoV-2 vaccination and associated factors among Chinese adults: A cross-sectional survey. International Journal of Environmental Research Public Health. 2021;18:1993.

Tables

Table 1. Basic information of the participants
|                | N   | %    |
|----------------|-----|------|
| Age group      |     |      |
| < 20 years     | 26  | 3.21 |
| 20-29 years    | 332 | 40.94|
| 30-39 years    | 253 | 31.2 |
| 40-49 years    | 131 | 16.15|
| 50-59 years    | 69  | 8.51 |
| Sex            |     |      |
| Male           | 407 | 50.18|
| Female         | 404 | 49.82|
| Location       |     |      |
| Shandong Province | 800 | 98.64|
| Other provinces | 11  | 1.36 |
| Education      |     |      |
| Middle school or below | 18  | 2.22 |
| High school    | 61  | 7.52 |
| University / College | 599 | 73.86|
| Graduate school or above | 133 | 16.4 |
| Occupation     |     |      |
| Professionals  | 294 | 36.25|
| Formal sector staff | 273 | 33.66|
| Student        | 182 | 22.44|
| Others         | 62  | 7.64 |
| Vaccines       |     |      |
| 1              | 294 | 36.25|
| 2              | 517 | 63.75|

**Table 2.** Knowledge, willingness and perceptions
| Knowledge on the vaccines | No knowledge | 35 | 4.32 |
|---------------------------|--------------|----|------|
| Knowing a little          | 566          |    | 69.79|
| Knowing a lot             | 210          |    | 25.89|
| Reasons to get vaccinated | Occupational exposure | 320 | 39.46|
| Planning to go abroad     | 421          |    | 51.91|
| No special reason or others | 70           |    | 8.63 |
| willingness to get vaccinated | Not willing | 10 | 1.23 |
| Fairly willing            | 408          |    | 50.31|
| Strongly willing          | 393          |    | 48.46|
| Recommendation to others  | Not willing  | 31 | 3.82 |
| fairly willing            | 533          |    | 65.72|
| Strongly willing          | 247          |    | 30.46|
| Perceived effectiveness   | Limited effectiveness | 22 | 2.71 |
| No idea                   | 460          |    | 56.72|
| Good effectiveness        | 329          |    | 40.57|
| Perceived safety          | Limited safety | 4  | 0.49 |
| No idea                   | 323          |    | 39.83|
| Good safety               | 484          |    | 59.68|
| Total                     | 811          |    |      |

**Table 3.** List of self-reported side effects
| Issue                              | N  | %   |
|------------------------------------|----|-----|
| Redness at the injection site      | 3  | 0.37|
| Swelling at the injection site     | 8  | 0.99|
| Hardening at the injection site    | 3  | 0.37|
| Burning sensation at the injection site | 2  | 0.25|
| Soreness in the injection site     | 46 | 5.67|
| Bruising at the injection site     | 2  | 0.25|
| Itching at the injection site      | 1  | 0.12|
| Fever                              | 4  | 0.49|
| Feeling cold                       | 2  | 0.25|
| Shaking Chill                      | 1  | 0.12|
| Oppression in chest                | 1  | 0.12|
| Headache                           | 11 | 1.36|
| Arthralgia                         | 2  | 0.25|
| Myalgia                            | 13 | 1.60|
| Neuralgia                          | 1  | 0.12|
| Dizziness                          | 9  | 1.11|
| Somnolence                         | 38 | 4.69|
| Nausea                             | 2  | 0.25|
| Diarrhea                           | 4  | 0.49|
| Anorexia                           | 1  | 0.12|
| Tiredness                          | 31 | 3.82|
| Eruption                           | 1  | 0.12|
| Eczema                             | 1  | 0.12|
| Elevated heart beat                | 1  | 0.12|
| Fatigue                            | 2  | 0.25|
| Hypopsia                           | 1  | 0.12|
| Weakness                           | 5  | 0.62|
| Emotional instability              | 2  | 0.25|
| Others | 2 | 0.25 |